Several GLP-1 agonists are part of this program, including: Exenatide: Results from a large, phase 2 trial in 2017 suggested that exenatide may slow Parkinsons progression
Those are two very different things
We also describe the development of incretin-based pharmacotherapy, starting with exendin- 4 and ending with the identification of multi-incretin hormone receptor agonists, which appear to be the next major step in the fight against T2DM and obesity
Worth a look if you support patients where sodium intake is a concern
Where these therapies are used, the evidence discusses slow titration, close monitoring with CGM, and attention to protein intake and muscle mass
"Im actually really happy that Im opening up about this because Im having my own journey with it," he said